☰

Hsing-Ju Tsai, Ph.D. - Publications

Affiliations: 
2011 Pharmacology and Toxicology University of California, Davis, Davis, CA 
Area:
Pesticide Biotechnology
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Liu JY, Tsai HJ, Morisseau C, Lango J, Hwang SH, Watanabe T, Kim IH, Hammock BD. In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors. Biochemical Pharmacology. PMID 26494425 DOI: 10.1016/J.Bcp.2015.10.013  0.402
2012 Kopkan L, Husková Z, Sporková A, Varcabová Š, Honetschlägerová Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, Bürgelová M, Vojtíšková A, Kujal P, Vernerová Z, Červenka L. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney & Blood Pressure Research. 35: 595-607. PMID 22948718 DOI: 10.1159/000339883  0.389
2012 Kim IH, Nishi K, Kasagami T, Morisseau C, Liu JY, Tsai HJ, Hammock BD. Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase. Bioorganic & Medicinal Chemistry Letters. 22: 5889-92. PMID 22901393 DOI: 10.1016/J.Bmcl.2012.07.074  0.449
2012 Ahn KC, Kasagami T, Tsai HJ, Schebb NH, Ogunyoku T, Gee SJ, Young TM, Hammock BD. An immunoassay to evaluate human/environmental exposure to the antimicrobial triclocarban. Environmental Science & Technology. 46: 374-81. PMID 22077920 DOI: 10.1021/Es202494D  0.349
2012 Ulu A, Appt S, Morisseau C, Hwang SH, Jones PD, Rose TE, Dong H, Lango J, Yang J, Tsai HJ, Miyabe C, Fortenbach C, Adams MR, Hammock BD. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. British Journal of Pharmacology. 165: 1401-12. PMID 21880036 DOI: 10.1111/J.1476-5381.2011.01641.X  0.635
2011 Liu JY, Qiu H, Morisseau C, Hwang SH, Tsai HJ, Ulu A, Chiamvimonvat N, Hammock BD. Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model. Toxicology and Applied Pharmacology. 255: 200-6. PMID 21741984 DOI: 10.1016/J.Taap.2011.06.017  0.615
2011 Honetschlägerová Z, Z Husková Z, Vaňourková Z, Sporková A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Červenka L, Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. The Journal of Physiology. 589: 207-19. PMID 21078594 DOI: 10.1113/Jphysiol.2010.199505  0.357
2010 Morisseau C, Inceoglu B, Schmelzer K, Tsai HJ, Jinks SL, Hegedus CM, Hammock BD. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. Journal of Lipid Research. 51: 3481-90. PMID 20664072 DOI: 10.1194/Jlr.M006007  0.343
2010 Tsai HJ, Hwang SH, Morisseau C, Yang J, Jones PD, Kasagami T, Kim IH, Hammock BD. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 40: 222-38. PMID 20359531 DOI: 10.1016/J.Ejps.2010.03.018  0.512
2010 Simpkins AN, Rudic RD, Roy S, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide hydrolase inhibition modulates vascular remodeling. American Journal of Physiology. Heart and Circulatory Physiology. 298: H795-806. PMID 20035028 DOI: 10.1152/Ajpheart.00543.2009  0.379
2009 Ahn KC, Gee SJ, Tsai HJ, Bennett D, Nishioka MG, Blum A, Fishman E, Hammock BD. Immunoassay for monitoring environmental and human exposure to the polybrominated diphenyl ether BDE-47. Environmental Science & Technology. 43: 7784-90. PMID 19921894 DOI: 10.1021/Es9009037  0.333
2009 Luria A, Morisseau C, Tsai HJ, Yang J, Inceoglu B, De Taeye B, Watkins SM, Wiest MM, German JB, Hammock BD. Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase. American Journal of Physiology. Endocrinology and Metabolism. 297: E375-83. PMID 19458064 DOI: 10.1152/Ajpendo.00131.2009  0.384
2009 Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. The American Journal of Pathology. 174: 2086-95. PMID 19435785 DOI: 10.2353/Ajpath.2009.080544  0.353
2009 Kasagami T, Kim IH, Tsai HJ, Nishi K, Hammock BD, Morisseau C. Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorganic & Medicinal Chemistry Letters. 19: 1784-9. PMID 19216074 DOI: 10.1016/J.Bmcl.2009.01.069  0.458
2009 Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C, Hammock BD. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. British Journal of Pharmacology. 156: 284-96. PMID 19154430 DOI: 10.1111/J.1476-5381.2008.00009.X  0.446
2008 EnayetAllah AE, Luria A, Luo B, Tsai HJ, Sura P, Hammock BD, Grant DF. Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. The Journal of Biological Chemistry. 283: 36592-8. PMID 18974052 DOI: 10.1074/Jbc.M806315200  0.326
2008 Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. The Journal of Pharmacology and Experimental Therapeutics. 327: 707-15. PMID 18815352 DOI: 10.1124/Jpet.108.142398  0.418
2008 Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Fiehn O, Hammock BD, Weiss RH. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. Journal of Cardiovascular Pharmacology. 52: 314-23. PMID 18791465 DOI: 10.1097/Fjc.0B013E318185Fa3C  0.621
2007 Kim IH, Tsai HJ, Nishi K, Kasagami T, Morisseau C, Hammock BD. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. Journal of Medicinal Chemistry. 50: 5217-26. PMID 17894481 DOI: 10.1021/Jm070705C  0.433
2007 Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. Journal of Cardiovascular Pharmacology. 50: 225-37. PMID 17878749 DOI: 10.1097/Fjc.0B013E3181506445  0.466
2007 Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. Journal of Medicinal Chemistry. 50: 3825-40. PMID 17616115 DOI: 10.1021/Jm070270T  0.528
2007 Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ. Soluble epoxide hydrolase: a novel therapeutic target in stroke. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 27: 1931-40. PMID 17440491 DOI: 10.1038/Sj.Jcbfm.9600494  0.356
2007 Huang H, Nishi K, Tsai HJ, Hammock BD. Development of highly sensitive fluorescent assays for fatty acid amide hydrolase. Analytical Biochemistry. 363: 12-21. PMID 17291440 DOI: 10.1016/J.Ab.2006.10.041  0.347
2007 Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, Hammock BD. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorganic & Medicinal Chemistry. 15: 312-23. PMID 17046265 DOI: 10.1016/J.Bmc.2006.09.057  0.491
2006 Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, Davis BB, Low R, Hammock BD, Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 103: 18733-8. PMID 17130447 DOI: 10.1073/Pnas.0609158103  0.331
2006 Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD. Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorganic & Medicinal Chemistry Letters. 16: 5439-44. PMID 16908134 DOI: 10.1016/J.Bmcl.2006.07.073  0.595
2006 Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorganic & Medicinal Chemistry Letters. 16: 5212-6. PMID 16870439 DOI: 10.1016/J.Bmcl.2006.07.009  0.435
2006 Ahn KC, Ma SJ, Tsai HJ, Gee SJ, Hammock BD. An immunoassay for a urinary metabolite as a biomarker of human exposure to the pyrethroid insecticide permethrin. Analytical and Bioanalytical Chemistry. 384: 713-22. PMID 16416099 DOI: 10.1007/S00216-005-0220-5  0.321
2005 Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. Journal of Medicinal Chemistry. 48: 3621-9. PMID 15887969 DOI: 10.1021/Jm0500929  0.452
Show low-probability matches.